triple agonist glp-1 glp 1 gip From Obesity to Metabolic Health: Why Retatrutide Is a Game-Changer Dual and Triple Gut Peptide

(22 December 2025, data last accessed)

In a response to questions about Pfizer ending the trial of its oral drug, a company spokesperson pointed Scientific American to the press release that announced that decision and said Pfizer is working on other early-stage oral drug candidates for weight loss, including one that works on a similar hormone to GLP-1 that is currently in phase 2 clinical trials

N Engl J Med 2021;385:173749

However, this evidence is limited, inconsistent, and does not demonstrate clinically significant effects comparable to prescription GLP-1 agonists

[DOI] [PMC free article] [PubMed] [Google Scholar] 269.Gribble F.M., Reimann F

Pratley R, Amod A, Hoff ST, et al